Kallikrein-6 is a protein that in humans is encoded by the KLK6 gene. [5] [6] [7] [8] Kallikrein-6 is also referred to as neurosin, protease M, hK6, or zyme. It is a 223 amino acid sequence, derived from its 244 original form, which contains a 16 residue presignal and 5 residue activation peptide. [9]
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. The encoded enzyme is regulated by steroid hormones. In tissue culture, the enzyme has been found to generate amyloidogenic fragments from the amyloid precursor protein, suggesting a potential for involvement in Alzheimer's disease. Multiple alternatively spliced transcript variants that encode different isoforms have been identified for this gene. [8]
The secondary structure consists of 13 beta-pleated sheets, 2 alpha-helices, 2 310-helices, and 8 loop regions. In terms of amino acid sequences, hK6 is most similar to myelencephalon-specific protease (MSP), which comes from the rat kvllikrein gene family. MSP and hK6 both target the peptide bond where arginine follows and they both automatically cleave themselves at their Arg positions. [10]
However, structurally, hK6 most resembles trypsin found in cows/oxen. Surrounding the active site, there are short loop regions that point away from the binding site. In the binding site, residues 189-195, 214-220, and 224-228 are found in addition to the Asp, His, and Ser residues. [11]
Alpha-synuclein build-up is commonly found in Dementia with Lewy bodies, Parkinson's disease, and multiple system atrophy patients, serving as a biomarker for infection. Thus, degradation of this protein is necessary to prevent infection. In mice brain samples, protease inhibitors were used to identify the protein responsible for alpha-synuclein degradation. Various serine protease inhibitors (aprotinin, phenylmethyl sulfonyl fluoride, leupeptin, and 4-(2-aminoethyl)-benzenesulfonyl fluoride). significantly affected the degradation pathway, which justifies the necessity for a serine protease to degrade alpha-synuclein.
Kallikrein inhibitor was introduced to the mice samples, and it successfully inhibited kallikrein function. In vitro studies utilizing purified kallikrein were also performed on alpha-synuclein, and it was effective in degrading alpha-synuclein. Both the inhibition and successful in vitro enzymatic activity demonstrates kallikrein as the degradation enzyme. [12]
While hK6 has contributed to disease prevention, it also has the potential to contribute to the spread of malignant tumor cells. As a degradation enzyme, it has the capability of degrading extracellular matrix proteins on both normal and malignant cells, which would enhance their abilities to migrate and to send signals. For example, fibronectin interacts with integral molecules as malignant cells try to migrate; by degrading it, malignant cells are able to migrate, attach, and send a signal to other malignant cells. [13]
Asp-102, His-57, and Ser-195 form a catalytic triad to specifically hydrolyze a peptide bond where Arg is towards the N terminus and a general amino acid is towards the C terminus. [14] It is believed to follow a similar pathway to other serine-type proteases. [15]
Serpins are a superfamily of proteins with similar structures that were first identified for their protease inhibition activity and are found in all kingdoms of life. The acronym serpin was originally coined because the first serpins to be identified act on chymotrypsin-like serine proteases. They are notable for their unusual mechanism of action, in which they irreversibly inhibit their target protease by undergoing a large conformational change to disrupt the target's active site. This contrasts with the more common competitive mechanism for protease inhibitors that bind to and block access to the protease active site.
Alpha 2-antiplasmin is a serine protease inhibitor (serpin) responsible for inactivating plasmin. Plasmin is an important enzyme that participates in fibrinolysis and degradation of various other proteins. This protein is encoded by the SERPINF2 gene.
Kallikreins are a subgroup of serine proteases, enzymes capable of cleaving peptide bonds in proteins. In humans, plasma kallikrein has no known paralogue, while tissue kallikrein-related peptidases (KLKs) encode a family of fifteen closely related serine proteases. These genes are localised to chromosome 19q13, forming the largest contiguous cluster of proteases within the human genome. Kallikreins are responsible for the coordination of various physiological functions including blood pressure, semen liquefaction and skin desquamation.
Tissue kallikrein is an enzyme. This enzyme catalyses the following chemical reaction
Kallikrein-1 is a protein that in humans is encoded by the KLK1 gene. KLK1 is a member of the peptidase S1 family.
Kallikrein-2 is a protein that in humans is encoded by the KLK2 gene, and is particularly associated with prostatic tissue.
Cathepsin D is a protein that in humans is encoded by the CTSD gene. This gene encodes a lysosomal aspartyl protease composed of a protein dimer of disulfide-linked heavy and light chains, both produced from a single protein precursor. Cathepsin D is an aspartic endo-protease that is ubiquitously distributed in lysosomes. The main function of cathepsin D is to degrade proteins and activate precursors of bioactive proteins in pre-lysosomal compartments. This proteinase, which is a member of the peptidase A1 family, has a specificity similar to but narrower than that of pepsin A. Transcription of the CTSD gene is initiated from several sites, including one that is a start site for an estrogen-regulated transcript. Mutations in this gene are involved in the pathogenesis of several diseases, including breast cancer and possibly Alzheimer disease. Homozygous deletion of the CTSD gene leads to early lethality in the postnatal phase. Deficiency of CTSD gene has been reported an underlying cause of neuronal ceroid lipofuscinosis (NCL).
Kallikrein-10 is a protein that in humans is encoded by the KLK10 gene.
Kallikrein-5, formerly known as stratum corneum tryptic enzyme (SCTE), is a serine protease expressed in the epidermis. In humans it is encoded by the KLK5 gene. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its expression is up-regulated by estrogens and progestins. Alternative splicing results in multiple transcript variants encoding the same protein.
Kallikrein-related peptidase 4 is a protein which in humans is encoded by the KLK4 gene.
Kallikrein-11 is a protein that in humans is encoded by the KLK11 gene.
Kallikrein-related peptidase 7 (KLK7) is a serine protease that in humans is encoded by the KLK7 gene. KLK7 was initially purified from the epidermis and characterised as stratum corneum chymotryptic enzyme (SCCE). It was later identified as the seventh member of the human kallikrein family, which includes fifteen homologous serine proteases located on chromosome 19 (19q13).
Kallikrein-13 is a protein that in humans is encoded by the KLK13 gene.
Kallikrein-8 is a protein that in humans is encoded by the KLK8 gene.
Kallikrein-14 is a protein that in humans is encoded by the KLK14 gene.
Kallikrein-15 is a protein that in humans is encoded by the KLK15 gene.
Kallikrein-12 is a protein that in humans is encoded by the KLK12 gene.
Kallikrein-related peptidase 9 also known as KLK9 is an enzyme which in humans is encoded by the KLK9 gene.
Kunitz domains are the active domains of proteins that inhibit the function of protein degrading enzymes or, more specifically, domains of Kunitz-type are protease inhibitors. They are relatively small with a length of about 50 to 60 amino acids and a molecular weight of 6 kDa. Examples of Kunitz-type protease inhibitors are aprotinin, Alzheimer's amyloid precursor protein (APP), and tissue factor pathway inhibitor (TFPI). Kunitz STI protease inhibitor, the trypsin inhibitor initially studied by Moses Kunitz, was extracted from soybeans.
Kallikrein 8 is an enzyme. This enzyme catalyses the following chemical reaction
PDB gallery | |
|---|---|
|
